DOCK4 as a Potential Biomarker Associated with Immune Infiltration in Stomach Adenocarcinoma: A Database Analysis.
DOCK4
TME
immune infiltration
prognostic biomarker
stomach adenocarcinoma
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
02
2022
accepted:
29
06
2022
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
19
7
2022
Statut:
epublish
Résumé
The involvement of dedicator for cytokinesis 4 (DOCK4), a guanine nucleotide exchange factor for Rac1, in immune infiltration in stomach adenocarcinoma (STAD) remains unclear. The UALCAN database was used to analyze the expression of the DOCK family. The Kaplan-Meier method and Gene Expression Profiling Interactive Analysis (GEPIA) databases were used to assess the prognostic value of the DOCK family in STAD. Furthermore, the correlation between expression of DOCK4 as well as other immune-related marker genes and tumor immune infiltration in STAD was explored using the TIMER and GEPIA websites. Subsequently, the relationship between DOCK4 expression and clinical characteristics was verified using the UALCAN database. Finally, DOCK4 mutation was analyzed via the TIMER2.0 and cBioPortal databases and the DOCK4 protein-protein interaction networks were constructed using the GeneMANIA and STRING websites. DOCK4 was found to be a new prognostic biomarker in STAD. DOCK4 expression in tumors was thoroughly evaluated relative to paracancerous tissues; overexpression of DOCK4 had a negative impact on the prognosis of patients with STAD. DOCK4 was found to be significantly associated with tumor immune infiltration in STAD. In summary, DOCK4 is a potential regulator of the recruitment and regulation of immune-infiltrating cells, thus serving as a valuable prognostic biomarker in STAD.
Identifiants
pubmed: 35846794
doi: 10.2147/IJGM.S357096
pii: 357096
pmc: PMC9286484
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6127-6143Informations de copyright
© 2022 Lu et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Natl Cancer Inst. 2015 Sep 15;107(12):djv256
pubmed: 26376684
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
World J Gastrointest Oncol. 2021 Sep 15;13(9):1184-1195
pubmed: 34616522
Ann Pharmacother. 2015 Aug;49(8):907-37
pubmed: 25991832
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
PPAR Res. 2021 Feb 3;2021:6629842
pubmed: 33613670
Mol Cancer. 2019 Jan 15;18(1):10
pubmed: 30646912
Clin Cancer Res. 2010 Mar 1;16(5):1662-72
pubmed: 20179239
Cancer Res. 2019 Sep 15;79(18):4557-4566
pubmed: 31350295
Mol Psychiatry. 2021 May;26(5):1505-1519
pubmed: 31388105
Gastric Cancer. 2017 Mar;20(2):217-225
pubmed: 26897166
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Genes Dev. 2015 Feb 1;29(3):250-61
pubmed: 25644601
Cell Signal. 2014 May;26(5):1082-8
pubmed: 24508479
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Gastric Cancer. 2016 Jan;19(1):198-205
pubmed: 25616808
Cell Res. 2017 Jan;27(1):109-118
pubmed: 27995907
Blood. 2006 Oct 1;108(7):2150-8
pubmed: 16772603
Dev Cell. 2018 Aug 20;46(4):410-425.e7
pubmed: 30078728
Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):E6359-68
pubmed: 26578796
Eur J Cell Biol. 2014 Oct;93(10-12):466-77
pubmed: 25022758
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Transl Oncol. 2018 Oct;11(5):1171-1187
pubmed: 30059832
J Clin Invest. 2013 Jul;123(7):2873-92
pubmed: 23778140
Nucleic Acids Res. 2018 Jul 2;46(W1):W60-W64
pubmed: 29912392
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Immunol Med. 2020 Mar;43(1):1-9
pubmed: 31822213
Mol Biol Evol. 2007 Jan;24(1):203-16
pubmed: 17035353
Br J Cancer. 2014 Mar 4;110(5):1307-15
pubmed: 24518591
Breast Cancer Res Treat. 2016 Dec;160(3):439-446
pubmed: 27744485
Prog Retin Eye Res. 2014 Nov;43:1-16
pubmed: 25016980
Gastric Cancer. 2016 Jan;19(1):42-52
pubmed: 25424150
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Cochrane Database Syst Rev. 2017 Aug 29;8:CD004064
pubmed: 28850174
Nat Cell Biol. 2012 Mar 11;14(4):366-74
pubmed: 22407364
J Exp Clin Cancer Res. 2018 Mar 27;37(1):71
pubmed: 29587866
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Biol Psychiatry. 2010 Aug 15;68(4):320-8
pubmed: 20346443
Int J Biol Markers. 2020 Mar;35(1):26-32
pubmed: 31841062
J Clin Immunol. 2013 Jan;33(1):55-67
pubmed: 22968740
Trends Cell Biol. 2007 Aug;17(8):383-93
pubmed: 17765544
J Immunol. 2012 Nov 1;189(9):4258-65
pubmed: 23018462
Nature. 2018 Jan 18;553(7688):347-350
pubmed: 29320474
J Gastrointest Oncol. 2015 Oct;6(5):561-9
pubmed: 26487950
Oncogene. 2020 Sep;39(37):5933-5949
pubmed: 32753649
Int J Biochem Cell Biol. 2015 Apr;61:103-14
pubmed: 25687035
Int J Oncol. 2016 Apr;48(4):1313-24
pubmed: 26892688
J Cancer Res Clin Oncol. 2010 Dec;136(12):1901-13
pubmed: 20217129
Int J Mol Sci. 2020 Jul 04;21(13):
pubmed: 32635504
J Clin Med. 2020 May 12;9(5):
pubmed: 32408477
J Biol Chem. 2013 Jul 5;288(27):20034-45
pubmed: 23720743
Curr Oncol Rep. 2019 Jun 24;21(8):67
pubmed: 31236716
Ann Surg. 2018 Feb;267(2):311-318
pubmed: 27763900
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Blood. 2012 May 10;119(19):4451-61
pubmed: 22461490
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
J Gastrointest Oncol. 2012 Sep;3(3):251-61
pubmed: 22943016
PLoS One. 2013 Nov 15;8(11):e81702
pubmed: 24260584
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Immunol. 2013 Apr 1;190(7):3661-9
pubmed: 23455509
J Cell Physiol. 2019 Dec;234(12):23202-23215
pubmed: 31215650
CA Cancer J Clin. 2021 May;71(3):264-279
pubmed: 33592120
Cancer Manag Res. 2020 Sep 29;12:9339-9349
pubmed: 33061623
Genome Biol. 2016 Nov 17;17(1):231
pubmed: 27855702
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
Lancet. 2018 Jul 14;392(10142):123-133
pubmed: 29880231